Next Article in Journal
Usability of EU-TIRADS in the Diagnostics of Hürthle Cell Thyroid Nodules with Equivocal Cytology
Previous Article in Journal
Changes in the Epidemiology of Hepatobiliary Disease Complicating Type 2 Diabetes over 25 Years: The Fremantle Diabetes Study
Previous Article in Special Issue
Mid-to Long-Term Survival of Total Knee Arthroplasty in Hemophilic Arthropathy
Open AccessArticle

The German Hemophilia Registry: Growing with Its Tasks

1
dhr Office, Paul-Ehrlich-Institut, Federal Institute for Vaccines and Biomedicines, 63225 Langen, Germany
2
Division Haematology/Transfusion Medicine, Paul-Ehrlich-Institut, Federal Institute for Vaccines and Biomedicines, 63225 Langen, Germany
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2020, 9(11), 3408; https://doi.org/10.3390/jcm9113408
Received: 28 September 2020 / Revised: 20 October 2020 / Accepted: 22 October 2020 / Published: 24 October 2020
(This article belongs to the Special Issue Diagnosis and Management of Hemophilia: Old and New Challenges)
Hemophilia is a rare heredity bleeding disorder that requires treatment for life. While few therapeutic options were available in the past, multiple recent breakthroughs have fundamentally altered and diversified hemophilia therapy, with even more new therapeutic options forthcoming. These changes are mirrored by significant regulatory and legal changes, which have redefined the role of hemophilia registries in the European Union (EU). This dual paradigm shift poses new regulatory, scientific but also structural requirements for hemophilia registries. The aim of this manuscript is to enumerate these significant challenges and to demonstrate their incorporation into the redesign of the German Hemophilia Registry (Deutsches Hämophilieregister, dhr). To identify the spectrum of hemophilia therapies and the degree of regulatory changes, a horizon screening was performed. Consequently, a core dataset for the dhr was defined by harmonization with regulatory guidelines as well as other hemophilia registries and by heeding the needs of different stakeholders (patients, clinicians, regulators, and scientists). Based on this information, a new registry structure was established, which is optimized for capturing data on new and established hemophilia therapies in a changing therapeutic and regulatory landscape View Full-Text
Keywords: hemophilia; patient registries; gene therapy; EHL clotting factor concentrates; nonreplacement therapies; inhibitors hemophilia; patient registries; gene therapy; EHL clotting factor concentrates; nonreplacement therapies; inhibitors
MDPI and ACS Style

Duda, H.; Hesse, J.; Haschberger, B.; Hilger, A.; Keipert, C. The German Hemophilia Registry: Growing with Its Tasks. J. Clin. Med. 2020, 9, 3408.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop